GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Godavari Drugs Ltd (BOM:530317) » Definitions » Return-on-Tangible-Asset

Godavari Drugs (BOM:530317) Return-on-Tangible-Asset : 3.84% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Godavari Drugs Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Godavari Drugs's annualized Net Income for the quarter that ended in Dec. 2023 was ₹49 Mil. Godavari Drugs's average total tangible assets for the quarter that ended in Dec. 2023 was ₹1,272 Mil. Therefore, Godavari Drugs's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 3.84%.

The historical rank and industry rank for Godavari Drugs's Return-on-Tangible-Asset or its related term are showing as below:

BOM:530317' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.4   Med: 3.41   Max: 14.68
Current: 3.4

During the past 13 years, Godavari Drugs's highest Return-on-Tangible-Asset was 14.68%. The lowest was 1.40%. And the median was 3.41%.

BOM:530317's Return-on-Tangible-Asset is ranked better than
57.2% of 1084 companies
in the Drug Manufacturers industry
Industry Median: 1.745 vs BOM:530317: 3.40

Godavari Drugs Return-on-Tangible-Asset Historical Data

The historical data trend for Godavari Drugs's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Godavari Drugs Return-on-Tangible-Asset Chart

Godavari Drugs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.77 2.54 4.72 5.45 3.40

Godavari Drugs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 4.39 2.67 2.69 3.84

Competitive Comparison of Godavari Drugs's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Godavari Drugs's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Godavari Drugs's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Godavari Drugs's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Godavari Drugs's Return-on-Tangible-Asset falls into.



Godavari Drugs Return-on-Tangible-Asset Calculation

Godavari Drugs's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=37.858/( (1014.11+1214.33)/ 2 )
=37.858/1114.22
=3.40 %

Godavari Drugs's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=48.836/( (1271.684+0)/ 1 )
=48.836/1271.684
=3.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Godavari Drugs  (BOM:530317) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Godavari Drugs Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Godavari Drugs's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Godavari Drugs (BOM:530317) Business Description

Traded in Other Exchanges
N/A
Address
Sardar Patel Road, 1-8-303/34, Mayfair, 1st Floor, Secunderabad, TG, IND, 500 003
Godavari Drugs Ltd is an India-based pharmaceutical company. It is principally engaged in the business activity of manufacturing pharmaceutical drugs. The firm's product includes Ciprofloxacin Lactate IH, A D Lactone, Ciprofloxacin Betaine, Enrofloxacin USP/EP/BP/IP, and Others. The company operates only one segment which is the manufacture and sale of Active Pharmaceutical Ingredients (API) and its intermediates.

Godavari Drugs (BOM:530317) Headlines

No Headlines